Onxeo Release: Judith Greciet, Invited As Guest Speaker At International Allicense Conference
Paris (France), Copenhagen (Denmark), March 31, 2015 [6:30 pm CET] - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that Judith Greciet, CEO of Onxeo, has been invited to participate to the 2015 Allicense Conference as a panelist for the session entitled "Eat or Be Eaten???The Specialty Pharma Survival Story".
As one of the active deal-making organizations during the last months, especially with the last year's acquisition and merger of TopoTarget by BioAlliance Pharma, Onxeo is a particularly compelling story, and certainly unique among mid-size European-based biotechs. Judith Greciet will contribute as a player and a witness to this very timely topic, with the recent Onxeo's story of increasing size and critical mass through a merger in order to emerge as new global playor in the orphan oncology drugs area.
Allicense Conference brings together professionals from the Pharma, Biotech and Financial communities. It offers opportunities for exchange of information and debate, especially in dealmaking, licensing and business development areas.
The conference takes place on May 5 and 6 (the session "Eat or Be Eaten - The Specialty Pharma Survival Story" is on the 6th at 2:15pm) at the Park Central Hotel in San Francisco.
About Allicense
The Allicense Conference is the leading event for dealmaking, licensing and business development professionals, and is hosted by Thomson Reuters, the leading provider of intelligence for the life sciences Business Development and Licensing market.
About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives designed to "make the difference". The Onxeo team is determined to develop innovative medicines that provide patients with hope and significantly improve their lives.
Key orphan oncology products at the advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive preliminary top-line results
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma
For more information, visit the website www.onxeo.com
Help employers find you! Check out all the jobs and post your resume.
As one of the active deal-making organizations during the last months, especially with the last year's acquisition and merger of TopoTarget by BioAlliance Pharma, Onxeo is a particularly compelling story, and certainly unique among mid-size European-based biotechs. Judith Greciet will contribute as a player and a witness to this very timely topic, with the recent Onxeo's story of increasing size and critical mass through a merger in order to emerge as new global playor in the orphan oncology drugs area.
Allicense Conference brings together professionals from the Pharma, Biotech and Financial communities. It offers opportunities for exchange of information and debate, especially in dealmaking, licensing and business development areas.
The conference takes place on May 5 and 6 (the session "Eat or Be Eaten - The Specialty Pharma Survival Story" is on the 6th at 2:15pm) at the Park Central Hotel in San Francisco.
About Allicense
The Allicense Conference is the leading event for dealmaking, licensing and business development professionals, and is hosted by Thomson Reuters, the leading provider of intelligence for the life sciences Business Development and Licensing market.
About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives designed to "make the difference". The Onxeo team is determined to develop innovative medicines that provide patients with hope and significantly improve their lives.
Key orphan oncology products at the advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive preliminary top-line results
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma
For more information, visit the website www.onxeo.com
Help employers find you! Check out all the jobs and post your resume.